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Abstract
Introduction: Sildenafil (Viagra®) is one of the drugs used in the first line therapy of male erectile
dysfunction (MED). We have recorded outcomes, adverse events and acceptability of Sildenafil
(Viagra) therapy in an unselected group of men presenting with ED to a British district general
hospital.
Methods: In this prospective observational study, 147 men with ED were seen since Oct 1999.
Study patients were reviewed at 4, 12 and 52 weeks. All the patients filled the International Index
of Erectile Function (IIEF) questionnaire and were asked about their willingness to pay (WTP) for
treatment.
Results: All suitable men accepted Viagra as first line therapy. 91% of our patients found sildenafil
treatment successful. 80% of these patients were willing to continue with sildenafil therapy. Side
effect profile of sildenafil was different in this study with much higher incidence of headache,
dyspepsia, flushing and abnormal vision. 92% of men with ED expect to be treated by the NHS. Of
those men eligible for treatment in the NHS, 30% qualify under the clinical categories and 18%
under the 'distress' category. Only 55% of those with cardiovascular risk factors qualify for NHS
treatment.
Conclusions: Sildenafil is widely accepted as first line therapy among British men with ED and has
a success rate of 91%. Nearly half of men with ED qualify for NHS treatment. Nearly half of those
with vascular risk factors do not qualify for NHS treatment. Most men with ED could possibly be
managed in primary care.
Background
Male erectile dysfunction (MED) (or impotence) has been
defined as the persistent inability to attain and maintain
an erection adequate to permit satisfactory sexual per-
formance [1]. The Massachusetts Male Aging Study report-
ed a combined prevalence of 52% for minimal, moderate,
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and complete impotence in non-institutionalised 40 to 70
years old men [2].
Over the last decade, a substantial body of evidence has
accumulated demonstrating the beneficial effects of phen-
tolamine, papaverine, and prostaglandin E1 (PGE1) when
injected intracavernously. However, both the method of
administration (self-injection) and the risks of major ad-
verse events, such as intracorporeal fibrosis and priapism
[3], strongly suggested the need for further therapeutic ad-
vances in the treatment of impotence. Transurethral al-
prostadil (as MUSE™) was the next to arrive on the scene,
but the response rate has been variable and enthusiasm
has waned [4]. The introduction of Sildenafil (Viagra)
provided the possibility of an acceptable, effective oral
therapy [5]. Sildenafil works by blocking the effects of the
enzyme Phosphodiesterase 5 (PDE-5), so prolonging the
effects of Nitric Oxide (NO) released in the penile cavern-
osal tissues from relevant nerve endings. The profile of
oral sildenafil (Viagra™) to date is that of an effective and
well tolerated on-demand pharmacological treatment for
men with erectile dysfunction [6].
With its unprecedented level of popularity and media
hype, Viagra brought it's own set of problems. The Gov-
ernment released its initial guidelines on treatment of im-
potence [7] "to find a sensible balance between treating
men with the distressing condition of impotence, and
protecting the resources of the NHS to deal with other pa-
tients". This was subsequently revised in June 1999 [8]
and serves as the current guideline for NHS prescription of
impotence treatments (Table. 1). It is of note that the De-
partment of Health included a non-clinical category – 'se-
vere distress' – eligible for treatment under the NHS. In
determining whether a patient is suffering from severe dis-
tress due to their ED[9], the following criteria were recom-
mended to be taken into account:
• Significant disruption to normal social and occupation-
al activity
• Marked effect on mood, behaviour, social and environ-
mental awareness
• Marked effect on interpersonal relationships
We receive multiple referrals of men with MED who ap-
pear suitable for sildenafil (Viagra) and assess them and
offer the full range of therapies. Many more men are pre-
senting to their GP's, some of whom are sufficiently expe-
rienced and interested in MED to be able to offer
treatment themselves or in consultation with a specialist.
However, published data on most clinical trials involving
sildenafil included only select groups of men with strin-
gent exclusion criteria. We have recorded outcomes, ad-
verse events and the acceptability of Sildenafil (Viagra)
therapy in an unselected group of men presenting with ED
to a British district general hospital.
Methods
In this prospective study, which was approved by the local
ethical committee, all the patients referred to this unit
with ED as their primary complaint were seen in a dedi-
cated andrology outpatient clinic. The self-administered
International Index of Erectile Function (IIEF) [10] ques-
tionnaire was filled prior to the consultation. Patient's
height and weight were measured followed by dipstick
testing of their urine (Bayer Multistix™). This was followed
by the consultation, which included a detailed history and
focussed physical examination (Visit 1). Suitable treat-
ment options were then discussed and patients were pro-
vided information about this study. Patients taking
nitrates, those with uncontrolled (or newly diagnosed)
cardiovascular disease and those already on sildenafil or
who had tried sildenafil and found it unsuccessful re-
ceived alternative treatments to sildenafil. If eligible, they
were started on 50 mg of sildenafil. Elderly men or those
with a significant cardiovascular history were started at the
lower dose of 25 mg. All men were advised on self-escala-
tion of the dose to a maximum of 100 mg, provided they
did not have a significant improvement in their erectile
Table 1: Government guidelines on the categories of patients 'el-
igible' for treatment of their ED under the NHS. Column 2 rep-
resents the number (percentage within parentheses) of patients 
with ED eligible for NHS treatment in this study.
Category eligible for NHS treatment No. (percent)
Distress 26 (17.6%)
Diabetes mellitus 22 (15%)
ED treatment prior to / on 14/09/1998 8 (5.4%)
Prostatectomy 5 (3.4%)
Prostate cancer 2 (1.4%)
Radical Pelvic Surgery 2 (1.4%)
Spinal Cord Injury 3 (2%)
Parkinson's Disease 1 (0.7%)
Multiple sclerosis 0
Poliomyelitis 0
Renal failure treated by dialysis or transplant 0
Severe pelvic injury 0
Single gene neurological disease 1 (0.7%)
Spina bifida 0
Total – eligible for NHS treatment 70 (47.6%)
Distress ('specialist' prescriptions required) 17.6%
Other categories (GP can prescribe) 30%BMC Urology 2002, 2 http://www.biomedcentral.com/1471-2490/2/4
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quality at the original dose and were able to tolerate the
possible side effects.
Patients were reviewed at 4, 12 and 52 weeks. The IIEF
questionnaire was administered at each visit and the glo-
bal score (GS – sum of responses to questions 1 – 15) and
erectile domain score (EDS – sum of responses to ques-
tions 1 – 5 and 15) calculated. At the first review (Visit 2),
side effects were recorded and patients were categorised as
'success' or 'failure' based on their response to the end of
treatment global efficacy question (GEQ) in the IIEF ques-
tionnaire – "Has the treatment you have been taking over
the past study interval improved your erections?" If any of
the patients had problems with dosing this was adjusted
at this review and they were seen again at 12 weeks (Visit
3). Those succeeding with treatment continued in the
study until the 52-week review (Visit 4) and were asked to
report any clinical problems in the interim. All the pa-
tients were questioned about the return of spontaneous
erectile activity at each review.
All the men underwent urine dipstick testing followed by
fasting blood glucose, testosterone and prolactin estima-
tion. Further tests were carried out where indicated on an
individual basis.
As part of this study patients were asked about their will-
ingness to pay (WTP) for the treatment of their ED (all op-
tions, not just sildenafil alone) at baseline and at each
review. The options presented to the patients is illustrated
in Table 2. The proportions of men in the various catego-
ries eligible for treatment under the NHS were recorded
prospectively (see Table 1). Results were analysed using
the SPSS software.
Results
A total of 147 men with ED were seen in the Andrology
Clinic between October 1999 and March 2000. Figure 1
provides a flow chart of the study's progress. Thirty-four
men were not included in the study. Their details are pro-
vided in Table 3. Thus, 113 men were enrolled in the
study. Of the 147 men, 117 were suitable for taking silde-
nafil out of whom 2 declined treatment with it, amount-
ing to an acceptance rate of 98.3%. Nineteen men had
already tried Viagra (13 successes and 6 failures) by the
time they were seen in the Andrology Clinic. At Visit 2, 14
men dropped out of the study (8 – lost to follow-up, 6 –
not interested in study anymore). Out of the remaining 99
men, 7 dropped out of the study by Visit 3 (1 – ejaculatory
dysfunction, 1 – unable to tolerate sildenafil, 1 – lost to
follow-up, 4 – not interested) and 8 (8.7% – 8/92) had
failed with sildenafil. After Visit 3, 84 men continued with
sildenafil, out of whom 10 dropped out of the study by
Visit 4 (6 – lost to follow-up, 1 – lack of partner, 2 – pros-
tate cancer surgery undertaken, 1 – not interested). All
these 10 were 'successes' with sildenafil therapy (at Visit 3)
and for the purposes of this study they were included in
the final analysis on an intention-to-treat basis. This was
achieved by using the last observation carried forward
(LOCF) method. The median follow-up period was 11
months (mean 9.1, range 1 – 14 months). Thus, 91.3%
(84/92) of men reported sildenafil therapy as successful.
The reported frequency of sexual intercourse in this popu-
lation was between 0.25 – 10 per week (mean 2.4). Eval-
uation of sexual function log revealed that there was good
concordance between the pre-study reported frequency
and logged frequency during the study period. Of the 113
men in the study, only 33 (29%) reported having some
amount of spontaneous erection, but not suitable for en-
joyable intercourse at Visit 1. Following sildenafil therapy,
82/99 (82.8%) men had improved erections (based on
GEQ) suitable for intercourse. Seventeen (17.2%) failed
treatment. There were no differences in the response rates
between the various aetiological groups. A total of 33/99
(33.3%) men reported return of spontaneous erections
suitable for penetrative intercourse, at least once, follow-
ing t re atment , of whom 14 (42.4%) did not have any
spontaneous erections suitable for intercourse prior to
therapy. Of the 74 men reviewed at Visit 4, 59 reported
that they would continue using Viagra on a long-term ba-
sis (79.7%). Three men had reported complete return of
spontaneous erections and had stopped using Viagra (1 at
Visit 2 and 2 at Visit 4).
Table 2: Willingness-to-pay (WTP) for treatment of ED. (GBP – 
Great Britain pounds)
1 I want to be treated by the NHS Free
2 I want to be treated by the NHS, but if I had to pay 








3 I don't think the NHS should pay for my treat-
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Figure 1
Flow diagram of patient population in the study.
147
Men with ED
113 suitable for 
sildenafil therapy
14 dropped out 
after Visit 1
VISIT 1
34 not included 
in study 
VISIT 2 99 in study
VISIT 3
84 in study
7 dropped out 
after Visit 2
8 failed with 
sildenafil therapy
10 dropped out 
after Visit 3 
VISIT 4 74 in studyBMC Urology 2002, 2 http://www.biomedcentral.com/1471-2490/2/4
Page 5 of 7
(page number not for citation purposes)
The mean IIEF GS at Visit 1 was 25.7 (median 22, range 5
– 64), at Visit 3, 56.9 (median 62, range 7 – 73) and at Vis-
it 4, 59.3 (median 60, range 18 – 73). The respective mean
IIEF EDS was 8.2 (median 6, range 0 – 28), 23.5 (median
27, range 1 – 30) and 25.2 (median 25, range 6 – 30).
There was no correlation between age and response to Via-
gra, although older men had relatively lower IIEF scores.
Of the 99 men reviewed, the optimal dose for achieving
erection satisfactory for sexual intercourse was: 25 mg – 6
(6.1%), 50 mg – 44 (44.4%), 75 mg – 1 (1%) and 100 mg
– 38 (38.4%). The side effects most commonly encoun-
tered were headache (24%), flushing (16%), dyspepsia
(12%), nasal congestion (10%), abnormal vision (5%),
thirst (2%) and dazed feeling (2%). Uncommon side ef-
fects included palpitations (1), dizziness (1) and penile
pain (1).  Se vere side ef fects neces sitat ed wit hdrawal of
Viagra in 2 patients (1 was a 'success' and the other a 'fail-
ure'). Out of 53 men who reported lack of side effects at
Visit 2, 6 developed some side effects at Visit 3. Converse-
ly, 11 men who had side effects at Visit 2 reported lack of
them at Visit 3. There were no changes in the side effect
profile between Visit 3 and Visit 4. Four men with Peyro-
nie's disease had used sildenafil – two reported success
with therapy while the other two failed. There were 2 iso-
lated reports of prolonged erection (lasting 20 – 30 min-
utes) that were painless, which did not recur. There were
no serious adverse events or deaths recorded during the
trial period.
Of the 147 men seen, 141 had expressed an option when
asked about their willingness-to-pay (WTP) for treatment.
Thirty men (21.3%) wanted ED treatment completely free
of charge (i.e., on the NHS), 100 (70.9%) wanted it free,
but were willing to pay some cost if required to do so and
11 (7.8%) felt that it was inappropriate for ED to be treat-
ed in the NHS and were willing to pay for it 'at cost'. Fol-
lowing treatment with sildenafil, those who failed to have
better erections were not willing to pay any amount, while
in those who succeeded there were no statistically signifi-
cant changes i.e. the 3 WTP groups did not show any sig-
nificant upward or downward trend following success
with sildenafil therapy.
Under the current Government guidelines, only 47.6% of
men with ED are eligible for treatment under the NHS
(see Table 1). Out of the 147, 58 patients (40%) had one
or more cardiovascular risk factors (hypertension, ischae-
mic heart disease, arrrythmia, congestive heart failure, dy-
slipidaemia or peripheral vascular disease). Only 32 of
these patients (i.e. 55% of those with CVS risk factors)
qualified for NHS treatment based on other grounds.
Discussion
Sildenafil, a potent PDE-5 inhibitor has been studied ex-
tensively in the context of clinical trials. To date its profile
as a safe treatment option in the management of ED re-
mains unchanged. This study aimed mainly at recording
the acceptance of the drug, its efficacy and safety profile
outside the scope of a trial i.e., in a study without any
stringent exclusion criteria.
Out of 117 men who were suitable for taking sildenafil,
the acceptance of sildenafil as a treatment option is high,
98.3% (115/117). Sildenafil was successful in treating ED
in 91.3% (84/92) of this study population. At the end of
the study period, 79.7% (59/74) of men wanted to con-
tinue treatment with sildenafil. The side effect profile of
sildenafil in this study would appear to be different from
previous published data [6] in that the incidence of head-
ache, flushing, dyspepsia and abnormal vision is higher,
but in the absence of a control group the significance of
this is uncertain. It must be noted that 13% of men who
reported side effects at Visit 2 reported complete lack of
them at Visit 3. It is of interest that there is a 2% incidence
each of thirst and 'dazed feeling' (reported by patients as
a 'muzzy head'). The physiology underlying this is un-
clear, although it could be related to PDE inhibition in the
brain, where the various PDE isoenzymes are in abun-
dance [11].
During the period following the licensing of sildenafil for
use in ED, an increase in the number of patients seeking
treatment for heretofore-untreated ED was widely antici-
pated. This institution did not find an increase in the
number of men referred with ED in the year following 14
September 1998, compared to the year preceding this
date. It is not clear though, if this anticipated increase in
the number of men with ED have been dealt with in the
primary care. Considering that the referral pattern from
Table 3: Details of men not included in the study.
Men presenting with ED as main complaint 147
Already using Viagra successfully 13
Already tried Viagra and failed 6
On nitrates 6
Cardiac opinion – Not suitable 2
Suspected venous leak 1
Rapid ejaculation 1
Psychological counselling required 1
Not interested 2
No partner – patient declined treatment 1
Declined Viagra specifically 1
Total no. of patients not included in study 34BMC Urology 2002, 2 http://www.biomedcentral.com/1471-2490/2/4
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primary to secondary care has not changed in this institu-
tion, we do not feel that this has happened.
Willingness-to-pay is a tool used to assess health benefits
perceived to be due to a health measure [12] – [13]. In this
study, there were no significant changes in the WTP with-
in or between the 3 WTP groups, in those who succeeded
with sildenafil therapy. This lack of change / trend in the
WTP seems more to reflect the perception of healthcare
delivery by the NHS, in that, in spite of successful treat-
ment of their ED, the patients were unwilling to change
their WTP category. The other possibility is that the grada-
tions or categories in WTP in this study were probably not
sufficiently wide to detect the changes. This study is based
in the real world and hence could not include further gra-
dations. It is also likely that if the condition were some-
thing more serious, for example, cancer, then the
treatment measure and its success may have impacted dif-
ferently on the perception.
It is of note that the mean frequency of intercourse in this
cohort of patients is higher than that quoted in the guide-
lines issued by the Department of Health [9]. Fifteen pa-
tients (10.2%) (Table 3, rows 2 – 5) would have required
specialist opinion (e.g. would have required a cardiolo-
gist, urologist or an andrologist in a tertiary referral centre
to have seen them prior to starting therapy for their ED),
while the rest could have been managed in primary care.
Conclusions
Oral sildenafil appears to be safe in the treatment of erec-
tile dysfunction in the real world. It is accepted widely by
our patients as first line treatment and is successful in 91%
of our patients. At the end of the study period 80% of the
patients were willing to continue with sildenafil therapy.
In our part of the United Kingdom, there is a large expec-
tation for ED to be treated in the NHS. Of those men eli-
gible for treatment of their ED in the NHS, 30% qualify
under the clinical categories and 18% under the 'distress'
category. This has implications on the local prescribing
policies and resources. Under the current guidelines, only
55% of men with one or more cardiovascular risk factors
qualify for treatment in the NHS. The majority of men
presenting with ED could be managed in primary care.
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